Samsung Biologics 1H sales exceeded ₩1 trillion for the first time since its establishment.

The company attributed its improved results to the rapid growth of its CMO business, the increased capacity utilization rate of its 3rd plant, and the increased exchange rate.

◆"Lands 7 contracts in 1H… the company’s 1st, 2nd, and 3rd plant is operating at full capacity"

On the 27th, Samsung Biologics publicly announced that it had recorded consolidated sales of ₩1.1627 trillion and an operating profit of ₩346.1 billion in the 1st half of this year.

Excluding the performance of its subsidiary Samsung Bioepis, the non-consolidated, se